Skip to content
Company Analysis

Takeda Pharmaceutical Company L TAK

A comprehensive view of key metrics, scores, and financial health for Takeda Pharmaceutical Company L

Overview of Takeda Pharmaceutical Company Limited

TAK NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Large Cap
Takeda Pharmaceutical Company Limited (TAK), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $20.87, about 18.7% overvalued vs fair value, +53.0% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth -1.7% ROE -2.1% Gross Margin 65.1% Div Yield 3.34%
USD 20.87
-0.19%
(Delayed)
• Vol 90d: 22.8%
52-Week Range
Market Cap
$67.28B
Enterprise Value
$95.69B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Good
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Good
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.takeda.com
HQ Tokyo
Employees 47,455
Fiscal year Mar 31

Next Events

Earnings Jan 28

Fair Value Snapshot

Bear Base Bull
$15
$17
$19
Current: $20.87 -19% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
JPY 4.5T
-1.7%%
Gross Profit
JPY 2.9T
-2.2%%
R&D Expense
JPY 675.9B
-7.4%%
Operating Income (EBIT)
JPY 5.8B
-98.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
18055.3%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

JPY 363.5B
58.0% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
3/4
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Takeda Pharmaceutical Company L's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
59
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.93), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.81), indicating reliable business model.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.35), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.18), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
56
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing TAK's balance between Growth (28.8%), Profitability (46.3%), and Safety (25.0%). Growth 29% Safety 25% Profitability 46%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

36th percentile vs peers
36
Key Signals
Revenue CAGR 3Y 3.8% 51p Rev Growth YoY -1.7% 33p TSR 28.7% 65p EPS CAGR 3Y -22.8% 33p EPS Growth YoY -2.41 8p
Strengths
  • Consistently strong margins across 3 metrics
Risks
  • EPS Growth YoY in bottom 20% of peers (-2.41)

Profitability

58th percentile vs peers
58
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

31th percentile vs peers
31
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Takeda Pharmaceutical Company L.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$16.96
- - -
-18.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000